HBW
CLBT icon

Hazlett, Burt & Watson’s Cellebrite CLBT Stock Holding History

Hazlett, Burt & Watson’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14K Hold
1,000
– – ﹤0.01% 640
2025
Q4 		$18K Hold
1,000
– – 0.01% 609
2025
Q3 		$19K Buy
+1,000
New +$15.7K 0.01% 567

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hazlett, Burt & Watson's CLBT Position: Q1 2026 in Review

Hazlett, Burt & Watson held its Cellebrite (CLBT) position steady in Q1 2026 at 1,000 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #640.

Hazlett, Burt & Watson first reported a position in CLBT in Q3 2025 and has held it in 3 quarters since. The position peaked at $19K in Q3 2025. 220 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • Hazlett, Burt & Watson held 1,000 shares of Cellebrite worth $14K as of Q1 2026.
  • Hazlett, Burt & Watson left its Cellebrite share count unchanged in Q1 2026.
  • Cellebrite made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #640 holding.
  • Hazlett, Burt & Watson first reported a position in Cellebrite in Q3 2025 and has held it in 3 quarters since.
  • Hazlett, Burt & Watson's Cellebrite position peaked at $19K in Q3 2025.
  • 220 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.